📣 VC round data is live. Check it out!

RxSight Valuation Multiples

Discover revenue and EBITDA valuation multiples for RxSight and similar public comparables like Ascom, Profound Medical, OraSure, Eurobio Scientific and more.

RxSight Overview

About RxSight

RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.


Founded

1997

HQ

United States

Employees

498

Financials (LTM)

Revenue: $132M
EBITDA: ($52M)

EV

$45M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

RxSight Financials

RxSight reported last 12-month revenue of $132M and negative EBITDA of ($52M).

In the same LTM period, RxSight generated $99M in gross profit, ($52M) in EBITDA losses, and had net loss of ($47M).

Revenue (LTM)


RxSight P&L

In the most recent fiscal year, RxSight reported revenue of $134M and EBITDA of ($36M).

RxSight is unprofitable as of last fiscal year, with gross margin of 77%, EBITDA margin of (26%), and net margin of (29%).

See analyst estimates for RxSight
LTMLast FY202320242025202620272028
Revenue$132M$134M$89M$140M$134M
Gross Profit$99M$103M$54M$99M$103M
Gross Margin75%77%60%71%77%
EBITDA($52M)($36M)($41M)($24M)($36M)
EBITDA Margin(39%)(26%)(46%)(17%)(26%)
EBIT Margin(42%)(36%)(56%)(26%)(36%)
Net Profit($47M)($39M)($49M)($27M)($39M)
Net Margin(35%)(29%)(55%)(20%)(29%)

Financial data powered by Morningstar, Inc.

RxSight Stock Performance

RxSight has current market cap of $252M, and enterprise value of $45M.

Market Cap Evolution


RxSight's stock price is $6.08.

RxSight share price decreased by 14.0% in the last 30 days, and by 60.2% in the last year.

RxSight has an EPS (earnings per share) of $-0.94.

See more trading valuation data for RxSight
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$45M$252M0.0%-14.0%-18.4%-60.2%$-0.94

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

RxSight Valuation Multiples

RxSight trades at 0.3x EV/Revenue multiple, and (0.9x) EV/EBITDA.

See NTM and 2027E valuation multiples for RxSight

EV / Revenue (LTM)


RxSight Financial Valuation Multiples

As of May 27, 2026, RxSight has market cap of $252M and EV of $45M.

RxSight has a P/E ratio of (5.4x).

LTMLast FY202320242025202620272028
EV/Revenue0.3x0.3x0.5x0.3x0.3x
EV/EBITDA(0.9x)(1.3x)(1.1x)(1.9x)(1.3x)
EV/EBIT(0.8x)(0.9x)(0.9x)(1.2x)(0.9x)
EV/Gross Profit0.5x0.4x0.8x0.5x0.4x
P/E(5.4x)(6.5x)(5.2x)(9.2x)(6.5x)
EV/FCF(1.8x)(2.3x)(1.0x)(2.0x)(2.3x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified RxSight Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

RxSight Margins & Growth Rates

RxSight decreased revenue by 4% but EBITDA grew by 71% in the last fiscal year.

In the most recent fiscal year, RxSight reported gross margin of 77%, EBITDA margin of (26%), and net margin of (29%).

See estimated margins and future growth rates for RxSight

RxSight Margins

Last FY202420252026202720282029
Gross Margin77%71%77%72%
EBITDA Margin(26%)(17%)(26%)(47%)
EBIT Margin(36%)(26%)(36%)(51%)
Net Margin(29%)(20%)(29%)(46%)
FCF Margin(14%)(16%)(14%)(26%)

RxSight Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(4%)57%(4%)(4%)
Gross Profit Growth(10%)84%4%(10%)
EBITDA Growth71%(42%)50%71%
EBIT Growth37%(26%)31%37%
Net Profit Growth52%(44%)42%52%
FCF Growth71%(52%)(14%)71%

Data powered by FactSet, Inc. and Morningstar, Inc.

RxSight Operational KPIs

RxSight's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.

RxSight's Rule of 40 is (51%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

RxSight's Rule of X is (57%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for RxSight
LTMLast FY202320242025202620272028
Rule of 40(37%)(51%)---
Bessemer Rule of X(35%)(57%)---
Revenue per Employee-$0.3M---
Opex per Employee-$0.3M---
R&D Expenses to Revenue29%29%33%25%29%
Opex to Revenue-112%117%97%112%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

RxSight Competitors

RxSight competitors include Ascom, Profound Medical, OraSure, Eurobio Scientific, Stratec, Median Technologies, Asterasys, Orchestra BioMed, Affluent Medical and Dong-A ST.

Most RxSight public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Ascom0.6x0.6x5.2x5.3x
Profound Medical13.0x10.2x(5.7x)(6.3x)
OraSure0.7x0.7x(2.0x)(2.1x)
Eurobio Scientific1.3x1.2x7.7x7.2x
Stratec1.3x1.2x9.4x9.0x
Median Technologies9.6x9.2x(14.2x)(14.3x)
Asterasys9.0x7.6x27.2x22.0x
Orchestra BioMed4.9x8.1x(3.2x)(2.4x)

This data is available for Pro users. Sign up to see all RxSight competitors and their valuation data.

Start Free Trial

RxSight Funding History

Before going public, RxSight raised $95M in total equity funding, across 4 rounds.


RxSight Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Apr-20Series ABiomedical Advanced Research and Development Authority (BARDA)$10M--
Mar-17Series HVisionary Venture Fund$21M-RxSight is a medical technology company that developed the Light Adjustable Lens (LAL), the first and only intraocular lens technology that enables doctors to customize and optimize vision for patients after cataract surgery. The company was founded in 1997 by Robert Grubbs and is headquartered in Los Angeles, California. Visionary Venture Fund, an Orange County-based ophthalmology-focused venture fund, closed its debut fund in May 2017 and announced it would invest up to $30 million across approximately a dozen ophthalmology companies over the following 18 months, with RxSight listed as a representative company receiving investment. The Visionary Venture Fund was led by Managing Partner Jeffry Weinhuff and included Key Opinion Leader partners Dr. Richard Lindstrom, Dr. Eric Donnenfeld, and Dr. Kerry Solomon, alongside other globally recognized leaders in cataract, cornea, and refractive surgery. RxSight later completed its initial public offering on July 30, 2021, listing on NASDAQ under ticker RXST at an implied valuation of approximately $442 million, having raised approximately $132 million in gross proceeds through the sale of 8.2 million shares at $16 per share.
Jun-15Undisclosed stageBalance Point Capital Partners; H.I.G. BioHealth Partners; Longitude Capital; RA Capital Management$52M--
Mar-14Series A-$13M--

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About RxSight

When was RxSight founded?RxSight was founded in 1997.
Where is RxSight headquartered?RxSight is headquartered in United States.
How many employees does RxSight have?As of today, RxSight has over 498 employees.
Who is the CEO of RxSight?RxSight's CEO is Ron Kurtz.
Is RxSight publicly listed?Yes, RxSight is a public company listed on Nasdaq.
What is the stock symbol of RxSight?RxSight trades under RXST ticker.
When did RxSight go public?RxSight went public in 2021.
Who are competitors of RxSight?RxSight main competitors include Ascom, Profound Medical, OraSure, Eurobio Scientific, Stratec, Median Technologies, Asterasys, Orchestra BioMed, Affluent Medical, Dong-A ST.
What is the current market cap of RxSight?RxSight's current market cap is $252M.
What is the current revenue of RxSight?RxSight's last 12 months revenue is $132M.
What is the current revenue growth of RxSight?RxSight revenue growth (NTM/LTM) is 2%.
What is the current EV/Revenue multiple of RxSight?Current revenue multiple of RxSight is 0.3x.
Is RxSight profitable?No, RxSight is not profitable.
What is the current EBITDA of RxSight?RxSight has negative EBITDA and is not profitable.
What is RxSight's EBITDA margin?RxSight's last 12 months EBITDA margin is (39%).
What is the current EV/EBITDA multiple of RxSight?Current EBITDA multiple of RxSight is (0.9x).
What is the current FCF of RxSight?RxSight's last 12 months FCF is ($25M).
What is RxSight's FCF margin?RxSight's last 12 months FCF margin is (19%).
What is the current EV/FCF multiple of RxSight?Current FCF multiple of RxSight is (1.8x).
How many companies RxSight has acquired to date?RxSight hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies RxSight has invested to date?RxSight hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to RxSight

Lists including RxSight

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial